Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed stage IV or recurrent NSCLC~* Measurable disease by RECIST 1.0~* Must have received at least one prior line of therapy for advanced lung cancer (no maximum number)~* Life expectancy of at least 12 weeks~Exclusion Criteria:~* Pregnant or breastfeeding~* Radiation within 2 weeks~* Cytotoxic chemotherapy or monoclonal antibodies within 4 weeks~* EGFR tyrosine kinase inhibitor within 2 weeks~* Other small molecule inhibitor within 2 weeks~* Experimental treatment within 30 days~* Prior treatment with any HSP90 or HDAC inhibitor compound~* Known and untreated brain metastases~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to AUY922~* Unresolved diarrhea greater than or equal to CTCAE version 4, grade 1~* Major surgery within 2 weeks of starting study drug or have not recovered from side effects of surgery~* Known disorders due to a deficiency in bilirubin glucuronidation~* Requiring use of therapeutic doses of warfarin (Coumadin)~* History of long QT syndrome~* History of clinically manifest ischemic heart disease, heart failure or left ventricular dysfunction~* Clinically significant ECG abnormalities~* Other clinically significant heart disease~* Currently receiving treatment with any medication which has a relative risk of prolonging the QTc interval or inducing Torsades de Pointes~* On a cardiac pacemaker~* Concurrent malignancies or invasive cancers diagnosed within 3 years except for adequately treated basal cell cancer of the skin or in situ cancer of the cervix~* Known to be HIV positive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AUY922 Treatment Arm (Type: EXPERIMENTAL): AUY922 administered once weekly via intravenous, 70 mg/m2

Based on this trial design, predict the completion outcome and termination type (if applicable).